Sumitomo Pharma Co., Ltd.
Financial Summary for the Second Quarter of Fiscal Year Ending March 2027 (IFRS) (Consolidated)
For the second quarter of the fiscal year ending March 2027, revenue was 266,490 million yen (up 17.3% year-over-year), core operating profit was 421 hundred million yen, and interim profit attributable to owners of the parent was 38,238 million yen. Full-year forecasts were revised to revenue of 565,000 million yen, core operating profit of 105,000 million yen, and profit for the year of 94,000 million yen. The dividend forecast was also updated. The performance was supported by a weaker yen and expansion in the U.S. market. Segments were consolidated into a single Pharmaceuticals segment. An earnings presentation is scheduled.
Key Figures
- Revenue: 266,490 million yen (Year-over-Year +17.3%)
- Core Operating Profit: 421 million yen
- Interim Profit: 38,238 million yen
- Full-Year Revenue Guidance: 565,000 million yen
AI要約
Overview of Results
In this interim report, revenue increased significantly year-over-year while core operating profit and operating profit declined substantially. The revenue growth reflected expansion in the U.S. market, the impact of a weaker yen, and structural effects from segment changes. The Financial Summary revises the full-year guidance to revenue of 565,000 million yen, core operating profit of 105,000 million yen, and profit for the year attributable to owners of the parent of 94,000 million yen. An earnings presentation will be held.
Impact for Shareholders and Outlook
The revision to the full-year guidance has prompted a reassessment of expectations for future profit growth. Integration into a single Pharmaceuticals segment is expected to improve operational transparency. Refer to the announced notice for details on the revised dividend forecast. Exchange rate assumptions and progress in the U.S. market will be key drivers of future performance.
Revenue Trend
Operating Profit Trend
Margin Analysis
Segment Revenue Breakdown
Guidance vs. Results Comparison
Sumitomo Pharma Co., Ltd.
Company overview · Stock price · Financial data · All IR
